title: MitraClip therapy in mitral regurgitation: a Markov model for the cost-effectiveness of a new therapeutic option.
abstract: Introduction Mitral regurgitation is a heart condition resulting from blood flowing from the left ventricle towards the left atrium, increasing the risk of heart failure and mortality. While surgery can greatly reduce these risks, some patients are not eligible, resulting in medication being their only therapeutic alternative. The MitraClip (Abbot Vascular) is a medical device that is percutaneously implanted and designed to eliminate leaking of the mitral valve. Methods The efficacy of the MitraClip strategy vs medical management was assessed using a 4-state Markov model based on the mitral regurgitation grade (mitral regurgitation grade 0, I/II, and III/IV, and death). At each 1-month cycle, patients were or were not hospitalized. The model analyzed a fictional population of 1000 patients over a 5-year period from a national Health Insurance perspective. The primary end-point was the number of deaths avoided. Data from the EVEREST II High Risk Study patients were used along with a literature review. Results At 5 years, among the 1000 patients, 276 deaths were found to be avoidable with the MitraClip strategy. The incremental cost-effectiveness ratio (ICER) was €93,363 per death avoided. The annual ICER was calculated to take into consideration excess costs resulting from the MitraClip over the first year (€29,984 vs €8557 for the reference strategy) and the reduction of costs in following years (€3122 for MitraClip vs €8557 for reference strategy). Thus, the mean ICER was calculated to be €20,720 per death avoided. Conclusion The MitraClip is a novel alternative therapy for mitral insufficiency in patients ineligible for surgery that may offer a medico-economic advantage.
authors.affiliation: a Cardiovascular , CHU Nantes , France ;
authors.forename: Patrice
authors.initials: P
authors.lastname: Guerin
authors.affiliation: b Health Economics, Stratégique Santé , Evry , France ;
authors.forename: Sandrine
authors.initials: S
authors.lastname: Bourguignon
authors.affiliation: b Health Economics, Stratégique Santé , Evry , France ;
authors.forename: Nicolas
authors.initials: N
authors.lastname: Jamet
authors.affiliation: c Epidemiology and Biostatistics, Capionis , Bordeaux , France.
authors.forename: Sébastien
authors.initials: S
authors.lastname: Marque
mesh_terms: D003362:Cost-Benefit Analysis; D005260:Female; D006333:Heart Failure / Q000191:economics / Q000517:prevention & control; D006801:Humans; D008297:Male; D008390:Markov Chains; D008944:Mitral Valve Insufficiency / Q000191:economics* / Q000401:mortality / Q000601:surgery*; D017059:Models, Econometric
keywords: Cost-effectiveness; Heart failure; Markov Model; MitraClip; Mitral regurgitation